Literature DB >> 24849246

Adherence to the 2011 American Gastroenterological Association medical position statement for the diagnosis and management of Barrett's esophagus.

A Menezes1, A Tierney2, Y-X Yang2,3, K A Forde2,3, M Bewtra2,3, D Metz3, G G Ginsberg3, G W Falk3.   

Abstract

Considerable variability exists in adherence to practice guidelines for Barrett's esophagus (BE). Rapid advances in management approaches to BE led to a new American Gastroenterological Association (AGA) medical position statement in 2011. Our aim was to assess how well members of the AGA Clinical Practice section adhered to these guidelines. A self-administered survey incorporating questions on diagnostic criteria, cancer risk estimates, screening, surveillance, and therapeutics for BE was distributed electronically to 5850 North American members of the AGA Clinical Practice section. The response rate was 470 of 2040 opened e-mails (23%). Intestinal metaplasia was required for diagnosis of BE by 90%, but the Prague classification was used by only 53% of those aware of it. The annual risk of progression to esophageal adenocarcinoma was reported as 0.1-0.5% by 76%. Screening practices were variable, with 35% screening all patients with chronic gastroesophageal reflux disease and 15% repeating endoscopy in patients with gastroesophageal reflux disease following a negative screening. Surveillance guidelines were followed by 79% for nondysplastic BE and 86% for low-grade dysplasia, with expert pathology confirmation of dysplasia reported by 86%. Proton pump inhibitor dosing was variable, with 18% administering twice-daily doses and 30% titrating dose to symptoms. Ablation therapy was recommended by 6% for nondysplastic BE, 38% for low-grade dysplasia, and 52% for high-grade dysplasia. There is satisfactory adherence to the new AGA guidelines with respect to diagnosis, cancer risk estimates, and surveillance intervals in a select group of respondents. However, adherence continues to be variable in the use of the Prague classification, screening, and dosing of antisecretory therapy. Use of ablation therapy increases with grade of dysplasia. The reason for continued variability in adherence to BE practice guidelines remains unclear, and more evidence-based guidance is required to enhance clinical practice.
© 2014 International Society for Diseases of the Esophagus.

Entities:  

Keywords:  Barrett's esophagus; endoscopic therapy; guideline; practice pattern

Mesh:

Year:  2014        PMID: 24849246     DOI: 10.1111/dote.12228

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   2.822


  8 in total

1.  Editorial: Best Practices in Surveillance of Barrett's Esophagus.

Authors:  Sachin Wani; Srinivas Gaddam
Journal:  Am J Gastroenterol       Date:  2017-07       Impact factor: 10.864

2.  High rate of missed Barrett's esophagus when screening with forceps biopsies.

Authors:  Mendel E Singer; Robert D Odze
Journal:  Esophagus       Date:  2022-07-22       Impact factor: 3.671

3.  Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.

Authors:  Aaron J Small; James L Araujo; Cadman L Leggett; Aaron H Mendelson; Anant Agarwalla; Julian A Abrams; Charles J Lightdale; Timothy C Wang; Prasad G Iyer; Kenneth K Wang; Anil K Rustgi; Gregory G Ginsberg; Kimberly A Forde; Phyllis A Gimotty; James D Lewis; Gary W Falk; Meenakshi Bewtra
Journal:  Gastroenterology       Date:  2015-04-24       Impact factor: 22.682

Review 4.  Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.

Authors:  Amrit K Kamboj; David A Katzka; Prasad G Iyer
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-10-21

5.  Interobserver reproducibility in pathologist interpretation of columnar-lined esophagus.

Authors:  Luca Mastracci; Nataniele Piol; Luca Molinaro; Francesca Pitto; Carmine Tinelli; Annalisa De Silvestri; Roberto Fiocca; Federica Grillo
Journal:  Virchows Arch       Date:  2015-11-12       Impact factor: 4.064

6.  Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Meta-Analysis and GRADE system.

Authors:  Chao Zhang; Joey S W Kwong; Rui-Xia Yuan; Hao Chen; Chang Xu; Yi-Pin Wang; Gong-Li Yang; Jin-Zhu Yan; Le Peng; Xian-Tao Zeng; Hong Weng; Jie Luo; Yu-Ming Niu
Journal:  Sci Rep       Date:  2017-01-19       Impact factor: 4.379

7.  Adherence to quality indicators and surveillance guidelines in the management of Barrett's esophagus: a retrospective analysis.

Authors:  Donevan Westerveld; Vikas Khullar; Lazarus Mramba; Fares Ayoub; Tony Brar; Mitali Agarwal; Justin Forde; Joydeep Chakraborty; Michael Riverso; Yaseen B Perbtani; Anand Gupte; Chris E Forsmark; Peter Draganov; Dennis Yang
Journal:  Endosc Int Open       Date:  2018-03-01

8.  Attending Training Courses on Barrett's Esophagus Improves Adherence to Guidelines: A Survey from the Italian Society of Digestive Endoscopy.

Authors:  Rocco Maurizio Zagari; Leonardo Henry Eusebi; Giuseppe Galloro; Stefano Rabitti; Matteo Neri; Luigi Pasquale; Franco Bazzoli
Journal:  Dig Dis Sci       Date:  2020-09-28       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.